PharmiNews

The Directory of Pharma Companies and News

Santhera

Santhera logo
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative pharmaceutical products for the treatment of orphan mitochondrial and neuromuscular diseases. Santhera's lead product Raxone is authorized in the European Union, Norway, Iceland and Liechtenstein for the treatment of Leber's hereditary optic neuropathy (LHON). For Duchenne muscular dystrophy (DMD), the second indication for Raxone, Santhera has filed a Marketing Authorization Application (MAA) in the European Union and Switzerland. In collaboration with the US National Institute of Neurological Disorders and Stroke (NINDS) Santhera is developing Raxone in a third indication, primary progressive multiple sclerosis (PPMS), and omigapil for congenital muscular dystrophy (CMD), all areas of high unmet medical need.
Category: Pharmaco
Category: Pharmaco

Santhera News

DateNews
2017-05-02Santhera Signs Distribution and Supply Agreement for Raxone® (idebenone) with Pharmathen for Greece and Cyprus (PDF)
2017-04-25Santhera becomes Founding Member of the Industry Advisory Council of the United Mitochondrial Disease Foundation (PDF)
2017-04-04Santhera’s Shareholders Approve all Board Proposals at Annual Shareholders’ Meeting (PDF)
2017-03-07Santhera Delivered Solid Performance in 2016 and Advances All Programs (PDF)
2017-02-10Santhera Successfully Places CHF 60 million Senior Convertible Bonds (PDF)
2017-02-10Santhera Launches Senior Convertible Bond Issue (PDF)
2017-01-31Santhera Nominates New Board Members for Election at Upcoming Annual Shareholders’ Meeting (PDF)
2017-01-26Santhera Reports Preliminary Key Financial Figures for 2016 and Provides Corporate Update (PDF)
2017-01-25Santhera Announces Combination of Two Shareholder Groups (PDF)
2017-01-20Santhera to Report 2016 Preliminary Key Financial Figures and Provide Corporate Update on January 26, 2017 (PDF)
2016-05-03Santhera Updates on Regulatory Filings for Raxone® (idebenone) in Duchenne Muscular Dystrophy (DMD)
2016-04-14Santhera Co-Sponsors and Presents at the First "Duchenne Pulmonary Outcomes Workshop" Organized by Parent Project Muscul...
2016-04-12Santhera Reports Increase in Product Sales, Positive Net Result for 2015 and Progress in All Programs
2016-01-27Santhera Reports Preliminary Key Financial Figures for 2015
2016-01-18Santhera Signs Distribution and Supply Agreement for Raxone® with Ewopharma Covering Eastern Europe and The Baltics
2015-12-02Santhera Completed Share Placement and Raised CHF 54.8 Million
2015-12-01Santhera Launches Placement of up to 500,000 New Shares Through an Accelerated Bookbuilding Procedure
2015-11-11Santhera Reports New Data and Updates on Regulatory Filings for Raxone® (idebenone) in Duchenne Muscular Dystrophy (DMD)
2015-10-22Santhera and Parent Project Muscular Dystrophy (PPMD) Announce Results of Benefit / Risk Survey in patients with Duchenn...
2015-10-01Santhera launches Raxone® in its first EU market
2015-09-15Santhera CEO Exercises Options and Increases his Shareholding in Santhera
2015-09-09Santhera Receives European Marketing Authorization for Raxone® in Leber's Hereditary Optic Neuropathy (LHON)
2015-09-03Santhera Reports Financial Results for the First Half Year and Transitions Towards Product Company
2015-08-19Santhera Receives Rare Pediatric Disease Designation from FDA for Idebenone for the Treatment of Duchenne Muscular Dystr...
2015-08-07Santhera Raised CHF 27.7 Million of New Capital
2015-07-31Santhera to Raise Capital Through Sale of Newly Created Shares
2015-07-20Santhera Announces First Patient Dosing with Omigapil in Congenital Muscular Dystrophy (CMD) and Full Patient Recruitmen...
2015-06-26CHMP recommends granting a marketing authorization for Santhera's Raxone® for the treatment of Leber's Hereditary Optic ...
2015-06-22Santhera Appoints Chief Financial Officer
2015-06-10Santhera Update on Pre-NDA Meeting with FDA on Raxone®/Catena® in Duchenne Muscular Dystrophy (DMD)
2015-05-11Santhera's Shareholders Approve all Board Proposals at Annual Shareholders' Meeting
2015-04-21Santhera's Positive Phase III Trial (DELOS) in Patients with Duchenne Muscular Dystrophy Published in The Lancet
2015-04-14Santhera Reports 2014 Financial Results and Significant Progress in All Programs
2015-04-09Santhera receives FDA Fast Track Designation for Raxone®/Catena® (idebenone) for theTreatment of Duchenne Muscular Dystr...
2015-03-11Principal Investigator to Present Phase III Data on Idebenone in Duchenne Muscular Dystrophy (DMD) at the Annual Meeting...
2015-01-30Santhera Extends Executive Management and Appoints Chief Commercial Officer
2015-01-23Santhera reports preliminary key financial figures for 2014
2014-11-25Santhera and Parent Project Muscular Dystrophy (PPMD) Team Up on Benefit/Risk Study in Duchenne Muscular Dystrophy
2014-09-26Santhera to Present Results from Phase III Study with Catena®/ Raxone® in Duchenne Muscular Dystrophy at the Internation...
2014-09-09Santhera Reports First Half 2014 Financial Results and Positive Developments in All Strategic Program
2014-08-15Santhera Receives CHF 13.4 Million Through Sale of Treasury Shares
2014-07-17Santhera Repositions Omigapil in Congenital Muscular Dystrophy and Initiates Clinical Development Program with Public-Pr...
2014-06-24ValuationLAB issues research report on Santhera
2014-06-05European Medicines Agency Validates Santhera's Marketing Authorization Application for Raxone® in Leber's Hereditary Opt...
2014-05-22Santhera Reports Positive Outcome for Catena®/Raxone® in Phase III DMD Trial Supported by Additional Respiratory Functio...
2014-05-15Santhera to Present at the Bio€quity 2014 Conference
2014-05-13Santhera Announces Successful Outcome of Phase III Study with Catena®/Raxone® in Duchenne Muscular Dystrophy
2014-05-07Santhera Files Marketing Authorization Application in European Union for Raxone® in the Treatment of LHON
2014-04-08Santhera Reports Financial Figures for 2013 and Progress towards Turnaround
2014-04-04Santhera to Present Financial Figures for 2013 and Outlook at Swiss Biotech Day 2014
2014-03-19Santhera Receives US Patent for Fipamezole in the Treatment of Neurodegenerative Diseases
2014-03-04Santhera Presents New Efficacy Data from an Expanded Access Program with Raxone® for the Treatment of Leber's Hereditary...
2014-02-27Santhera Raises CHF 1 Million in Private Placement with IGLU Group
2014-01-21Temporary Authorization for Use Granted for Santhera's Raxone® for the Treatment of Leber's Hereditary Optic Neuropathy ...
2014-01-21Autorisation Temporaire d'Utilisation accordée pour Raxone® dans le traitement de la Neuropathie Optique Héréditaire de ...
2013-11-26Santhera's Phase III program with Catena®/Raxone® in Duchenne Muscular Dystrophy on track to deliver pivotal data early ...
2013-10-30Santhera Secures Up to CHF 10 Million in Equity Financing From YA Global
2013-09-03Santhera Closes License-Back Deal with Takeda For European Rights to Catena® in Duchenne Muscular Dystrophy
2013-08-30Santhera Successfully Concludes Restructuring in First Half Year of 2013
2013-07-11Santhera Initiates Collaboration with the European Vision Institute Clinical Research Network in LHON
2013-06-06Santhera Secures Exclusive Rights from NIH for a Novel Approach for the Treatment of Primary Progressive MS
2013-05-13Santhera's Shareholders Support Business Continuation and Evaluation of Strategic Options
2013-04-18Santhera Publishes Agenda for Annual Shareholders' Meeting
2013-04-16Independent DSMB Recommends Continuation of Santhera's Phase III Trial of Catena® in Duchenne Muscular Dystrophy
2013-04-16Santhera Reports 2012 Financial Figures and Announces Restructuring
2013-03-22Santhera Withdraws Marketing Authorization Application for Raxone® in LHON
2013-02-28Santhera Explores Strategic Options; Updates Financial Calendar
2013-02-27Santhera to Discontinue Sale of Catena® in Canada
2013-01-18Santhera Receives a Negative Opinion on its Marketing Authorization Application for Raxone®. Plans to Request Re-examina...
2012-11-16Santhera expects CHMP opinion on its MAA for Raxone® early 2013
2012-08-31Santhera Reports Stable Product Sales and Substantially Reduced Expenses and in First Half Year of 2012
2012-04-23Santhera Shareholders Approve all Board Proposals at Annual Shareholders' Meeting
2012-04-11Santhera Joins EU-funded EndoStem Consortium in Preparation for Clinical Study with Omigapil in Congenital Muscular Dyst...
2012-02-24Santhera Reports Stable Product Sales in 2011 and Cash Reserves of CHF 23.4 Million Following Completion of Restructurin...
2012-01-24Santhera and Ipsen Renegotiate Fipamezole Licensing Agreement
2011-10-19Santhera Presents Clinical Data of Catena® in Duchenne Muscular Dystrophy at the 2011 Congress of the World Muscle Socie...
2011-09-12Santhera to Present at Biotech in Europe Investor Forum
2011-08-29Santhera Announces Interim Financial Results for the First Half Year of 2011 and Restructuring Plans to Concentrate on C...
2011-08-24Santhera Obtains US Patent for Use of Catena® in the Treatment of Muscular Dystrophies
2011-08-23Disclosure of shareholdings in accordance with articles 20 and 21 SESTA
2011-07-27Publication in BRAIN Highlights Medical Potential of Santhera's Catena® in Leber's Hereditary Optic Neuropathy
2011-07-22Santhera's Marketing Authorization Application for Idebenone in LHON Accepted for Review by European Medicines Agency
2011-06-06Santhera Presents Nonclinical Data in LHON at the Joint Congress of SOE/AAO 2011
2011-05-27Data from Santhera's RHODOS Study to Be Presented at the European Neurological Society 2011 Meeting
2011-05-19Santhera to Present at BioEquity Europe
2011-05-09Santhera Presents Data from 2-Year Open-Label Intervention Study with Catena® in Duchenne Muscular Dystrophy at the MYOL...
2011-05-05Santhera Presents Positive Data from IONIA Open-Label Extension Study in Friedreich's Ataxia at the Fourth International...
2011-04-13Santhera Pharmaceuticals to Present at the 2011 American Academy of Neurology Annual Meeting
2011-04-07Santhera Publishes 2010 Annual Report
2011-04-05Publication Highlights Mode of Action for Santhera's Catena® and its Relevance for Mitochondrial Disorders
2011-02-25Santhera 2010 Results (news kit)
2011-02-25Santhera Reports 2010 Revenue of CHF 20.6 million and Prepares for MAA Filing in LHON
2011-02-18Fipamezole Transition from Biovail completed - Program Well Advanced Towards Phase III
2011-02-08Santhera Obtains US and Canadian Patents for Use of Omigapil for the Treatment of Congenital Muscular Dystrophy
2011-02-02Statement
2011-01-25Santhera Statement
2011-01-19Santhera to Present at the European Life Science CEO Forum
2011-01-05Santhera to Present at the Biotech Showcase 2011
2010-12-07Santhera Obtains European Patent for Use of Omigapil for the Treatment of Congenital Muscular Dystrophy
2010-10-25Santhera Regains Full Rights to Fipamezole in North America
2010-10-14Santhera Licenses Melanocortin-4 Receptor Antagonist Program to BioLineRx
2010-09-29Santhera Prepares for Pivotal Study with Omigapil in Congenital Muscular Dystrophy
2010-09-22Santhera Announces Intent To File Marketing Authorization Application for Leber's Hereditary Optic Neuropathy
2010-09-14Santhera Releases Additional Clinical Data Supporting the Use of Catena® in LHON
2010-09-03Santhera Reports 2010 Interim Financial Results with Significant Reduction in Net Loss and Strong Increase in Product Sa...
2010-09-03Santhera and Ipsen Enter into Licensing Agreement for Fipame-zole for the Treatment of Dyskinesia in Parkinson's Disease
2010-08-13Santhera Obtains European Patent for Use of Catena®/Sovrima® in the Treatment of Muscular Dystrophies
2010-07-15Data from Santhera's Catena® in Leber's Hereditary Optic Neuropathy Will Be Presented at the mitoNET Congress for Mitoch...
2010-06-16Santhera's Catena® Improved Vision in Patients with Leber's Hereditary Optic Neuropathy; Regulatory Submissions Planned ...
2010-05-20Santhera's MICONOS Trial with Catena®/Sovrima® in Friedreich's Ataxia Misses Primary Endpoint
2010-02-26Santhera 2009 Results (news kit)
2010-02-26Santhera Reports Strong 2009 Revenues of CHF 22.3m and Is Financed Beyond 2011
2009-12-07Santhera Presents New Data on MC-4R Antagonist Program for Treatment of Cancer Cachexia
2009-11-03Santhera Receives Grant from Association Française contre les Myopathies for its Omigapil Program in Congenital Muscular...
2009-10-05Santhera Reports Closing of Juvantia Acquisition and Final Upfront Payment from Partner Biovail
2009-09-04Santhera Reports Solid 2009 Interim Financial Results; Well Funded into H2 2011
2009-09-02Initiation of Pivotal Phase III Study with Catena®/Sovrima® (Idebenone) in Duchenne Muscular Dystrophy
2009-08-31Santhera to Implement Named Patient Program for Catena® in Europe
2009-08-24Santhera and Biovail Enter into License Agreement to Develop and Commercialize JP-1730/Fipamezole in North America
2009-08-17Santhera Acquires Juvantia and Secures All Rights to JP-1730/Fipamezole
2009-08-03Santhera Enrolls Last Patient in RHODOS Study Evaluating Catena® in Leber's Hereditary Optic Neuropathy
2009-07-06Santhera Aligns Resources and Plans to Restructure Drug Discovery
2009-06-30Santhera's FJORD Phase IIb Study Demonstrates Efficacy of JP-1730/Fipamezole for the Treatment of Dyskinesia in Parkinso...
2009-06-26Santhera Enters Agreement with Columbia University to Investigate Additional Potential of Catena® in MELAS
2009-06-24Santhera and NIH Collaborate To Evaluate Catena® in Primary Progressive Multiple Sclerosis
2009-05-19Santhera's US Phase III IONIA Trial in Friedreich's Ataxia Misses Primary Endpoint
2009-04-22Santhera Enrolls Last Patient in Phase IIb FJORD study with JP-1730/Fipamezole in Dyskinesia in Parkinson's Disease
2009-04-03Santhera Proposes Changes to its Board of Directors
2009-03-20Publication Highlights Potential of Santhera's Oral MC4-Receptor Antagonist Program for Treatment of Cancer Cachexia
2009-02-27Santhera 2008 Results (news kit)
2009-02-27Santhera Reports Financial Results 2008 and Successful First Product Launch
2008-12-11Santhera Enrolls Last Patient in European Phase III Trial Evaluating SNT-MC17/Idebenone in Friedreich's Ataxia
2008-11-19CHMP Confirms Original Opinion on Santhera's SNT-MC17/Idebenone for Treatment of Friedreich's Ataxia
2008-11-07Santhera Presents Preclinical Data on Oral MC4 Receptor Antagonists for Treatment of Cancer Cachexia at AICR Research Co...
2008-11-06Santhera Raises CHF 15.9 Million in Private Placement with Strategic Investor Ares Life Sciences
2008-10-31Santhera Enrolls Last Patient in Pivotal US Phase III with SNT-MC17/Idebenone in Friedreich's Ataxia
2008-10-10Santhera Launches CATENA® in Canada
2008-09-25Publication in European Heart Journal Highlights Potential of Santhera's SNT-MC17/idebenone in Duchenne Muscular Dystrop...
2008-08-22Santhera's 2008 Interim Results Reflect Advances in Clinical Development and Preparation for First Product Launch
2008-08-15Santhera's Omigapil Receives Orphan Drug Designation from FDA and EMEA
2008-08-08Santhera Provides Update on Clinical/Regulatory Processes with SNT-MC17/Idebenone for the Treatment of Friedreich's Atax...
2008-07-24Santhera's Ongoing Studies Prevent CHMP Review under Small Patient Populations Guideline - Company Expects Negative CHMP...
2008-07-24Santhera Receives First Product Approval: Health Canada Approves Catena® for Treatment of Friedreich's Ataxia
2008-05-28Santhera Presents Efficacy Data of SNT-317 in Congenital Muscular Dystrophy at International Congress of Myology
2008-04-11Santhera Presents Efficacy Data of SNT-MC17 in DMD at AAN Annual Meeting
2008-02-29Santhera 2007 results (news kit)
2008-02-29Santhera Reports Financial Results and Significant Operational Progress for 2007
2007-11-29Health Canada Accepts Santhera's Submission for Marketing Authorization of SNT-MC17 in Friedreich's Ataxia
2007-11-12Santhera Showcases Potential and Progress of its Clinical Development Pipeline
2007-11-09Santhera Starts Phase IIb Clinical Trial with JP-1730 in Dyskinesia in Parkinson's Disease
2007-10-29Santhera Reports Encouraging, First Data from Phase IIa Clinical Trial with SNT-MC17 in Duchenne Muscular Dystrophy
2007-10-24Santhera's CSO Thomas Meier Receives BioValley Award for Scientific and Entrepreneurial Merits
2007-10-04Swissmedic Accepts Santhera's Filing of SNT-MC17 in Friedreich's Ataxia
2007-09-28Santhera Announces Start of US Phase III Clinical Trial with SNT-MC17 in Friedreich's Ataxia and Provides Details on Stu...
2007-09-21Santhera to Seek Canadian Market Approval for SNT-MC17 in Friedreich's Ataxia
2007-09-07Publication in LANCET Neurology Highlights Potential of Santhera's SNT-MC17 for Friedreich's Ataxia
2007-08-17Santhera's 2007 Interim Results Reflect Increased Investment in Advanced Development Pipeline
2007-08-16European EMEA acceptance of Marketing Authorization Application filing for SNT-MC17 in Friedreich's Ataxia by Santhera
2007-08-02Santhera and Takeda Extend European Marketing Collaboration for SNT-MC17 into Duchenne Muscular Dystrophy
2007-07-02Santhera Licenses Omigapil for Treatment of Rare Neuromuscular Diseases
2007-03-28Santhera Announces Appointment of Cesare Mondadori as Head of Research
2007-03-02Santhera 2006 results (news kit)
2007-03-02Santhera Reports Successful 2006
2007-03-01Santhera Board Proposes the Election of Klaus Schollmeier to the Company's Board
2007-01-31Santhera Updates Development Strategy for SNT-MC17/idebenone in Friedreich's Ataxia in the US
2007-01-31Santhera Intends Early Filing in Europe for SNT-MC17/idebenone in Friedreich's Ataxia
2006-11-30Santhera and Biozentrum Basel participate in the pan-European TREAT-NMD initiative to advance the treatment of rare neur...
2006-11-24Santhera announces exercise of over-allotment option
2006-11-13NIH and Santhera Announce Positive Results of Study with SNT-MC17/idebenone in Friedreich's Ataxia (FRDA)
2006-11-03Santhera prices IPO at CHF 90 per share and raises CHF 88.5 million
2006-10-23Santhera announces an Initial Public Offering and subsequent listing on the SWX Swiss Exchange
2006-10-06NIH Completes Collaborative Phase II Study with Santhera's compound SNT-MC17/idebenone in Friedreich's Ataxia (FRDA)
2006-10-05Santhera Raises up to EUR 15 million in Oversubscribed Series C Financing
2006-09-26Santhera Targets Third Indication - Leber's Hereditary Optic Neuropathy (LHON) - with its Lead Compound SNT-MC17/idebeno...
2006-09-22Santhera Appoints MJ Roach as Vice President Marketing and Sales
2006-09-15Santhera Appoints New Board Directors
2006-09-05Santhera and Juvantia to Collaborate on Development of Phase II Product for Dyskinesia in Parkinson's Disease
2006-01-03Santhera Announces Management Buy-Out of the Graffinity Drug Discovery Technology Business
2005-12-20Santhera Raises CHF 25 Million (Euro 16 Million) Via a Further Closing of its 2005 B Financing Round
2005-12-15Santhera starts European Phase III Study with its Lead Compound SNT-MC17 (idebenone) in Friedreich's Ataxia
2005-11-02Santhera and the NIH Collaborate to Evaluate SNT-MC17 in Friedreich's Ataxia
2005-10-19Santhera Targets New Indication with its Lead Compound
2005-10-12Cellzome and Santhera's business unit, Graffinity, awarded € 2.2 million grant from German Government
2005-08-17Biovitrum and Santhera sign an exclusive license and collaboration agreement for the development of DPP-IV inhibitors fo...
2005-08-03Santhera and Takeda Establish Collaboration to Develop and Market Idebenone (SNT-MC17) in Neuromuscular Disease
2005-05-07Santhera Presents at the International Congress of Myology
2005-05-03Santhera Pharmaceuticals Announces the Appointment of Barbara A. Heller as Chief Financial Officer
2005-02-24Santhera Reaches Milestone in Serono Drug Discovery Collaboration
2004-12-17Santhera Pharmaceuticals AG Completes First Round of Financing Raising EURO 14 Million
2004-11-30Santhera Pharmaceuticals Announces the Appointment of Pierre Vankan, Ph.D. as Vice President, Drug Development and Globa...
2004-10-07Santhera Pharmaceuticals and Genzyme Enter Into Option and License Agreement for Discovery of Therapies for Muscle Disea...
2004-09-08GRAFFINITY PHARMACEUTICALS AG AND MYOCONTRACT AG MERGE TO FORM SANTHERA PHARMACEUTICALS AG
-0001-11-30Santhera Nominates New Board Members for Election at Upcoming Annual Shareholders’ Meeting (PDF)
Brought to you by PharmiWeb.com - Latest Jobs in Pharma
Brought to you by www.pharmiweb.com - Latest Jobs in Pharma.